Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multi...
Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background No targeted therapies are available for KRAS -mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS -mutant cancers. We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in pr...
Alternative Titles
Full title
Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751229708
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751229708
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(12)70489-8
